Physician profile
Navid R Homayouni
NPI 1558456855
$4,589.30
in general payments reported to CMS, 2019-2025
10 companies · $3,688 in 2025
The $3,688 reported for 2025 was more than what 86% of Nuclear Radiology providers received nationally (typical 2025 total: $145).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2022: $278 · 2023: $125 · 2024: $389 · 2025: $3,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613 · Travel and Lodging: $1,589 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.81 |
| Travel and Lodging | $1,588.56 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $3,563.44 | 2024-2025 | Illuccix |
| Progenics Pharmaceuticals, INC. | $383.70 | 2022-2024 | Pylarify |
| Jubilant Draximage, INC. | $189.80 | 2025 | Ruby-Fill |
| Ge Healthcare | $183.36 | 2025 | |
| Advanced Accelerator Applications | $110.00 | 2019 | |
| Siemens Medical Solutions USA, INC. | $50.70 | 2022 | |
| Cardinal Health 414 LLC | $35.64 | 2024 | |
| Pfizer INC. | $26.09 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.42 | 2025 | |
| Curium US LLC | $22.15 | 2025 | Detectnet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navid Homayouni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.